A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

BACKGROUND: The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of therapy. Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of response to cetuximab. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Balko, Justin M, Black, Esther P
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687459/
https://www.ncbi.nlm.nih.gov/pubmed/19439077
http://dx.doi.org/10.1186/1471-2407-9-145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687459/
https://www.ncbi.nlm.nih.gov/pubmed/19439077
http://dx.doi.org/10.1186/1471-2407-9-145

Ejemplares similares